News

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study’s end. Side effects were ...
It's little secret that America has a weight problem. For decades, Americans have embraced and abandoned countless ...
Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...
Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...
Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.
Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...
Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...
Eli Lilly shares are now positive for the year, up 10% since the start of January.